Categories: News

Yield10 Bioscience to Present at the H.C. Wainwright 25th Annual Global Investment Conference

WOBURN, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (Nasdaq: YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that management will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held on September 11-13, 2023, at the Lotte New York Palace Hotel.

President and Chief Executive Officer Oliver Peoples, Ph.D. will present a corporate overview that will also include a business update. The presentation will be available on demand on September 11, 2023 beginning at 7:00am ET. Dr. Peoples will also be available to participate in one-on-one meetings with investors who are registered to attend the conference.

A live webcast of the presentation and a replay will be available on the Investor Relations section of the Company’s website at IR Events & Presentations | Yield10 Bioscience, Inc.

About Yield10 Bioscience

Yield10 Bioscience, Inc. is an agricultural bioscience company that is using its differentiated trait gene discovery platform, the “Trait Factory”, to develop improved Camelina varieties for the production of proprietary seed products, and to discover high value genetic traits for the agriculture and food industries. Our goals are to efficiently establish a high value seed products business based on developing superior varieties of Camelina for the production of feedstock oils for renewable diesel, PHA bioplastics and omega-3 (EPA, DHA+EPA) oils, and to license our yield traits to major seed companies for commercialization in major row crops, including corn, soybean and canola. Yield10 is headquartered in Woburn, MA and has a Canadian subsidiary, Yield10 Oilseeds Inc., located in Saskatoon, Canada.

For more information about the company, please visit www.yield10bio.com, or follow the Company on X (formerly Twitter)Facebook and LinkedIn.

(YTEN-G)

Contacts:

Yield10 Bioscience:
Lynne H. Brum, (617) 682-4693, LBrum@yield10bio.com

Investor Relations:
Bret Shapiro, (561) 479-8566, brets@coreir.com
Managing Director, CORE IR

Media Inquiries:
Eric Fischgrund, eric@fischtankpr.com
FischTank PR

Staff

Recent Posts

Defence’s Successful Results on Its AccuTOX Anti-Cancer ARM Vaccine Creates a Potent Second-Generation Anti-Cancer ARM-002 Vaccine

Vancouver, British Columbia--(Newsfile Corp. - March 26, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB:…

44 mins ago

Nobul AI Corp and Check-Cap Ltd Enter into Definitive Business Combination Agreement

Proposed business combination to create a North American technology company with an AI-driven fintech marketplace.…

5 hours ago

Dr. Ji Han’s NY Spine Care Offers Cutting-Edge Interventional Pain Management

NEW YORK, NY / ACCESSWIRE / March 25, 2024 / Chronic pain affects millions of…

8 hours ago

FendX Technologies Announces Second Closing of Non-Brokered Private Placement and Announces Further Upsizing to $2 million

Oakville, Ontario--(Newsfile Corp. - March 25, 2024) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF)…

11 hours ago

VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update

Conference call to discuss financial and operational results scheduled for Tuesday, March 26 at 8:30…

11 hours ago

Brüush Receives Additional Delisting Notification to Address at Hearing

VANCOUVER, BC / ACCESSWIRE / March 25, 2024 / Bruush Oral Care Inc. (NASDAQ:BRSH) (the…

11 hours ago